

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number  
**WO 2005/014110 A1**

(51) International Patent Classification<sup>7</sup>: **A61P 37/04**,  
A61K 39/39, 9/127

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(21) International Application Number:  
PCT/EP2004/008190

(22) International Filing Date: 22 July 2004 (22.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:  
60/488,799 22 July 2003 (22.07.2003) US

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW. ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(71) Applicant (*for all designated States except US*): CYTOS BIOTECHNOLOGY AG [CH/CH]; Wagistrasse 25, CH-8952 Schlieren (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BACHMANN, Martin, F. [CH/CH]; Goldackerweg 8, CH-8472 Seuzach (CH). MANOLOVA, Vania [BG/CH]; Pestalozzistrasse 41, CH-8032 Zürich (CH). STORNI, Tazio [CH/CH]; Via Aldesago 10, CH-6962 Viganello (CH).

(74) Agent: WICHMANN, Hendrik; Isenbruck Bösl Hörschler Wichmann Huhn, Prinzregentenstrasse 68, 81675 München (DE).

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations  
— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CPG-PACKAGED LIPOSOMES

(57) Abstract: Liposomes are known to enhance the activity of K- (B-) type CpGs which trigger the production of IL-12. In the present invention, the surprising finding was made that liposomes also enhance the activity of D- (A-) type CpGs, leading to the production of IFN $\alpha$  in vivo. These findings are relevant for the humans situation, since IFN $\alpha$  rather than IL-12 is the key cytokine for the induction of Th 1 responses and anti-viral protection in humans.



WO 2005/014110 A1

## CPG-PACKAGED LIPOSOMES

### BACKGROUND OF THE INVENTION

#### 5 Field of the Invention

The present invention is related to the fields of vaccinology, immunology and medicine. The invention provides compositions and methods for enhancing production of IFN $\alpha$  in an animal by binding or enclosing and packaging, respectively, of at least one A-type CpG, preferably oligonucleotides containing at least one non-methylated CpG  
10 sequence. Preferred liposomes are cationic liposomes. The invention can be used to induce IFN $\alpha$  in vivo, particularly useful for the treatment of chronic viral diseases, cancer and short-term prophylaxis from pathogen-infection.

#### Related Art

The essence of the immune system is built on two separate foundation pillars: one  
15 is specific or adaptive immunity which is characterized by relatively slow response-kinetics and the ability to remember; the other is non-specific or innate immunity exhibiting rapid response-kinetics but lacking memory. Lymphocytes are the key players of the adaptive immune system. Each lymphocyte expresses antigen-receptors of unique specificity. Upon recognizing an antigen via the receptor, lymphocytes proliferate and  
20 develop effector function. Few lymphocytes exhibit specificity for a given antigen or pathogen, and massive proliferation is usually required before an effector response can be measured - hence, the slow kinetics of the adaptive immune system. Since a significant proportion of the expanded lymphocytes survive and may maintain some effector function following elimination of the antigen, the adaptive immune system reacts faster  
25 when encountering the antigen a second time. This is the basis of its ability to remember.

In contrast to the situation with lymphocytes, where specificity for a pathogen is confined to few cells that must expand to gain function, the cells and molecules of the innate immune system are usually present in massive numbers and recognize a limited number of invariant features associated with pathogens (Medzhitov, R. and Janeway,  
30 C.A., Jr., *Cell* 91:295-298 (1997)). Examples of such patterns include

- 2 -

lipopolysaccharides (LPS), non-methylated CG-rich DNA (CpG) or double stranded RNA, which are specific for bacterial and viral infections, respectively.

Most research in immunology has focused on the adaptive immune system and only recently has the innate immune system entered the focus of interest. Historically, the adaptive and innate immune system were treated and analyzed as two separate entities that had little in common. Such was the disparity that few researchers wondered why antigens were much more immunogenic for the specific immune system when applied with adjuvants that stimulated innate immunity (Sotomayor, E. M., et al., Nat. Med. 5:780 (1999); Diehl, L., et al., Nat. Med. 5:774 (1999); Weigle, W. O., Adv. Immunol. 30:159 (1980)). However, the answer posed by this question is critical to the understanding of the immune system and for comprehending the balance between protective immunity and autoimmunity.

Stimulation of innate immunity alone is able to confer non-specific protection from infection, mainly via induction of cytokines. In addition, topical and local application of stimulators of innate immunity may be able to protect from tumor growth. DNA rich in non-methylated CG motifs (CpG), as present in bacteria and most non-vertebrates, is an important example of such a stimulator of innate immunity, since CpGs exhibit a potent stimulatory activity on B cells, dendritic cells and other APC's in vitro as well as in vivo. Although bacterial DNA is immunostimulatory across many vertebrate species, the individual CpG motifs may differ. In fact, CpG motifs that stimulate mouse immune cells may not necessarily stimulate human immune cells and vice versa.

Interestingly, two types of CpGs exist, those that activate B cells and trigger the production of IL-12 (B-type, also known as K-type) and those that activate plasmacytoid DCs and induce the production of IFN $\alpha$  (A-type, also known as D-type). In general, B-type CpGs exhibit maximal activity only if the natural phosphodiester bond of the DNA is replaced by non-natural phosphothioester bond. This modification not only stabilizes the CpGs and protects them from degradation by nucleases but also leads to enhanced recognition by TLR9. This is different for A-type CpGs, which are optimally recognized by TLR9 in their natural phosphodiester form, while phosphothioester stabilized A-type CpGs are poorly recognized (Krieg AM, Annu Rev Immunol. 2002;20:709-60).

Therefore, the usefulness of A-type CpGs is often limited in vivo, since they are rather unstable in vivo. Thus, they exhibit unfavourable pharmacokinetics. In order to

- 3 -

render A-type CpG-oligonucleotides more potent, it would be essential to apply them in a protected form. One possibility to stabilize A-type CpGs is to package them into virus-like particles (VLPs), which protect them from degradation (WO03/024481). However, this leads to a concomitant strong T and B cell response against the VLPs. While this is desirable if the VLPs are used as vaccines, this is a disadvantage for non-specific stimulation of innate immunity, since it precluded multiple applications.

It has previously been shown that application of B-type CpGs in liposomes enhances their capacity to induce production of IL-12 in vitro and in vivo (J Immunol 167: 3324). However, liposomes were reported not to enhance the potency of A-type CpGs (WO 03/040308). We now found surprisingly, that liposomes strongly enhance the in vivo efficacy of A-type CpGs.

#### SUMMARY OF THE INVENTION

This invention is based on the surprising finding that liposomes not only enhance the in vivo efficacy of B-type CpGs but also of A-type CpGs. This now offers the unexpected opportunity to induce high levels of IFN $\alpha$  in vivo using A-type CpGs.

In a first embodiment, the invention provides a composition for inducing the production of IFN $\alpha$  in an animal comprising a liposome and an A-type unmethylated CpG-containing oligonucleotide, where the oligonucleotide is bound to or enclosed by the liposome.

In a preferred embodiment, the at least one A-type CpG comprises at least one CpG motif, wherein all the nucleotides of the at least one CpG motif are composed of phosphodiester nucleotides. In a further preferred embodiment, the at least one A-type CpG comprises poly G motifs at the 5' and 3' ends, and wherein preferably all of the G nucleotides are phosphodiester nucleotides.

In a preferred embodiment of the invention, the A-type (also called D-type) CpG comprises or alternatively consists of a phosphodiester oligonucleotide, preferably comprising a palindromic sequence, wherein preferably the palindromic sequence is GACGATCGTC (SEQ ID NO: 16). In a most preferred embodiment, the A-type CpG has the sequence GGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO: 3) or is a shorter version thereof.

In a preferred embodiment, the liposome is neutral, anionic, cationic, stealth or cationic stealth. In a most preferred embodiment, the liposome is a cationic liposome. In a further preferred embodiment the liposome is smaller than 200 nm.

In a further aspect, the present invention provides a method for enhancing the  
5 production of IFN $\alpha$  in an animal comprising introducing into the animal a composition of the invention.

In another aspect of the present invention, a vaccine is provided comprising an immunologically effective amount of the composition of the invention together with a pharmaceutically acceptable diluent, carrier or excipient.

10 The route of injection is preferably subcutaneous or intramuscular, but it would also be possible to apply the A-type CpG-containing liposomes intradermally, intranasally, intravenously or directly into the lymph node. In an equally preferred embodiment, the A-type CpG-containing liposomes mixed with antigen are applied locally, near a tumor or local viral reservoir.

15 It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are intended to provide further explanation of the invention as claimed.

#### BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES

Fig. 1 shows that phosphodiester (type A) oligonucleotides efficiently activate  
20 human CD8+ T cells from peripheral blood. Peripheral blood mononuclear cells (PBMC) were obtained from heparinized blood of healthy volunteers by ficoll (Amersham Biosciences, Sweden) density centrifugation. PBMC were resuspended in 10% FCS RPMI and plated in 96-U-bottom well plate at  $0.3 \times 10^6$  cells/well. Cells were treated with the indicated concentrations of oligonucleotides or left untreated for 24h, at 37°C. PBMC  
25 were stained on ice with a combination of anti-CD8-FITC and anti-CD69-APC (all from Becton Dickinson, USA). Cells were acquired and analyzed using FACSCalibur (Becton Dickinson, USA).

Fig. 2 shows that phosphothioate (type B) oligonucleotides efficiently activate  
30 human B cells. Peripheral blood mononuclear cells were (PBMC) obtained from heparinized blood of healthy volunteers by ficoll (Amersham Biosciences, Sweden) density centrifugation. PBMC were resuspended in 10% FCS RPMI and plated in 96-U-

- 5 -

bottom well plate at  $0.3 \times 10^6$  cells/well. Cells were treated with the indicated concentrations of oligonucleotides or left untreated for 24h, at 37°C. PBMC were stained on ice with a combination of anti-CD19-PE and anti-CD69-APC (all from Becton Dickinson, USA). Cells were acquired and analyzed using FACSCalibur (Becton Dickinson, USA).

Fig. 3 shows that only phosphodiester (Type A) oligonucleotides induce IFN alpha secretion from human PBMC. Peripheral blood mononuclear cells (PBMC) were obtained from heparinized blood of healthy volunteers by ficoll (Amersham Biosciences, Sweden) density centrifugation. PBMC were resuspended in 10% FCS RPMI and plated in 96-U-bottom well plate at  $0.3 \times 10^6$  cells/well. Cells were treated with the indicated concentrations of oligonucleotides or left untreated for 24h, at 37°C. IFN alpha, released in the supernatants was measured by ELISA using an antibody set (Cat. # 71100-1) from PBL Biomedical Laboratories, USA.

Fig. 4 shows that phosphothioester (type B) oligonucleotides induce IL-12 secretion from human PBMC. Peripheral blood mononuclear cells were (PBMC) obtained from heparinized blood of healthy volunteers by ficoll (Amersham Biosciences, Sweden) density centrifugation. PBMC were resuspended in 10% FCS RPMI and plated in 96-U-bottom well plate at  $0.3 \times 10^6$  cells/well. Cells were treated with the indicated concentrations of oligonucleotides or left untreated for 24h, at 37°C. IL-12, released in the supernatants was measured by ELISA using an antibody pair provided from Becton Dickinson (C8.3 and C8.6 clones).

Fig. 5 shows that phosphodiester (type A) oligonucleotides induce IFN alpha secretion from human plasmacytoid DC (pDC). pDC were isolated from human PBMC by magnetic activated cell sorting (MACS). PBMC from buffy coats were labeled with anti-BDCA-2 mAb coupled to magnetic beads (Milteniy, Germany) according to manufacturer's protocol. Labeled cells were positively selected by passing PBMC through a LS column. The purity of pDC was controlled by staining them with anti-BDCA-4-APC mAb (Milteniy). pDC were plated at  $0.04 \times 10^6$ /well and treated with G10, 2006 or left untreated. Twenty four hours later IFN alpha released in the supernatants was measured by ELISA, as described in the legend of figure 3.

Fig. 6 shows that phosphothioester-stabilized G10 (G10 PS) fails to activate human T cells. Peripheral blood mononuclear cells (PBMC) were obtained from

- 6 -

heparinized blood of healthy volunteers by ficoll (Amersham Biosciences, Sweden) density centrifugation. PBMC were resuspended in 10% FCS RPMI and plated in 96-U-bottom well plate at  $0.3 \times 10^6$  cells/well. Cells were treated with the indicated concentrations of oligonucleotides or left untreated for 24h, at 37°C. IFN alpha, released  
5 in the supernatants was measured by ELISA using an antibody set (Cat. # 71100-1) from PBL Biomedical Laboratories, USA.

Fig. 7 shows that 1668pt but not 1668po or G6 is able to enhance CTL responses in vivo. Fig. 7A: Mice were immunized with 100 ug of p33-VLPs (HBcAg with genetically fused the p33 epitope) alone or mixed with 1668pt or 1668po CpGs (20  
10 nmol). Twelve days later, mice were challenged ip with recombinant vaccinia virus expressing LCMV GP ( $1 \times 10^6$  pfu) and viral titers were determined in ovaries 5 days later. Fig. 7B: The bacteriophage Q $\beta$  capsid was used as VLP, to which the p33 peptide was chemically coupled, and co-delivered with the G6 CpG. Mice were left untreated or immunized with 90 ug of Q $\beta$  p33-VLPs mixed with G6 CpGs (20 nmol). Twelve days  
15 later, mice were challenged ip with recombinant vaccinia virus expressing LCMV GP ( $1 \times 10^6$  pfu) and viral titers were determined in ovaries 5 days later.

Fig. 8 shows that G6 in liposomes is able to enhance p33-specific immunity. Fig. 8A: Liposomes containing 1 mg/ml p33 peptide (KAVYNFATM) (SEQ ID NO: 13) alone or with 100 nmol/ml CpGs (1668 or G6) were produced. Subsequently, groups of  
20 C57BL/6 mice were vaccinated with the liposomal preparations (doses of 100 ug p33 peptide alone or with 10 nmol 1668 or G6 per mouse) and p33-specific T cell responses were assessed by tetramer-staining 8 days later. Fig. 8B: At day 12, liposome-treated mice were challenged ip with recombinant vaccinia virus expressing LCMV-GP ( $4 \times 10^6$  pfu) and viral titers were determined in ovaries 5 days later.

## 25 DETAILED DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the  
30 preferred methods and materials are hereinafter described.

- 7 -

## 1. Definitions

Animal: As used herein, the term "animal" is meant to include, for example, humans, sheep, horses, cattle, pigs, dogs, cats, rats, mice, birds, reptiles, fish, insects and arachnids.

5       Antibody: As used herein, the term "antibody" refers to molecules which are capable of binding an epitope or antigenic determinant. The term is meant to include whole antibodies and antigen-binding fragments thereof, including single-chain antibodies. Most preferably the antibodies are human antigen binding antibody fragments and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, single-chain Fvs  
10 (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a V<sub>L</sub> or V<sub>H</sub> domain. The antibodies can be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine, rabbit, goat, guinea pig, camel, horse or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated  
15 from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulins and that do not express endogenous immunoglobulins, as described, for example, in U.S. Patent No. 5,939,598 by Kucherlapati et al.

The compositions and methods of the invention are also useful for treating cancer by stimulating non-specific immunity against cancer which may enhance specific  
20 immunity against tumor antigens. A "tumor antigen" as used herein is a compound, such as a peptide, associated with a tumor or cancer and which is capable of provoking an immune response. In particular, the compound is capable of provoking an immune response when presented in the context of an MHC molecule. Tumor antigens can be prepared from cancer cells either by preparing crude extracts of cancer cells, for example,  
25 as described in Cohen, et al., Cancer Research, 54:1055 (1994), by partially purifying the antigens, by recombinant technology or by de novo synthesis of known antigens. Tumor antigens include antigens that are antigenic portions of or are a whole tumor or cancer polypeptide. Such antigens can be isolated or prepared recombinantly or by any other means known in the art. Cancers or tumors include, but are not limited to, biliary tract  
30 cancer; brain cancer; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; intraepithelial neoplasms; lymphomas; liver cancer; lung cancer (e.g. small cell and non-small cell); melanoma;



neuroblastomas; oral cancer; ovarian cancer; pancreas cancer; prostate cancer; rectal cancer; sarcomas; skin cancer; testicular cancer; thyroid cancer; and renal cancer, as well as other carcinomas and sarcomas.

5 Allergens also serve as antigens in vertebrate animals. The term "allergen", as used herein, also encompasses "allergen extracts" and "allergenic epitopes." Examples of allergens include, but are not limited to: pollens (*e.g.* grass, ragweed, birch and mountain cedar); house dust and dust mites; mammalian epidermal allergens and animal danders; mold and fungus; insect bodies and insect venom; feathers; food; and drugs (*e.g.*, penicillin).

10 Antigenic determinant: As used herein, the term "antigenic determinant" is meant to refer to that portion of an antigen that is specifically recognized by either B- or T-lymphocytes. B-lymphocytes responding to antigenic determinants produce antibodies, whereas T-lymphocytes respond to antigenic determinants by proliferation and establishment of effector functions critical for the mediation of cellular and/or humoral  
15 immunity.

Antigen presenting cell: As used herein, the term "antigen presenting cell" is meant to refer to a heterogeneous population of leucocytes or bone marrow derived cells which possess an immunostimulatory capacity. For example, these cells are capable of generating peptides bound to MHC molecules that can be recognized by T cells. The  
20 term is synonymous with the term "accessory cell" and includes, for example, Langerhans' cells, interdigitating cells, dendritic cells, B cells and macrophages. Under some conditions, epithelial cells, endothelial cells and other, non-bone marrow derived cells may also serve as antigen presenting cells.

Bound: As used herein, the term "bound" refers to binding that may be covalent,  
25 *e.g.*, by chemically coupling the unmethylated CpG-containing oligonucleotide to a liposome, or non-covalent, *e.g.*, ionic interactions, hydrophobic interactions, hydrogen bonds, etc. Covalent bonds can be, for example, ester, ether, phosphoester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like. The term also includes the enclosement, or partial enclosement, of a substance. The term "bound"  
30 is broader than and includes terms such as "coupled," "fused," "enclosed" and "attached." Moreover, with respect to the CpG being bound to the liposome, the term "bound" also includes the enclosement, or partial enclosement, of the CpG. Therefore, with respect to

- 9 -

the CpG being bound to the liposome the term "bound" is broader than and includes terms such as "coupled," "fused," "enclosed", "packaged" and "attached." For example, the CpG can be enclosed by the liposome without the existence of an actual binding, neither covalently nor non-covalently, such that the oligonucleotide is held in place by  
5 mere "packaging."

CpG: As used herein, the term "CpG" refers to an oligonucleotide which contains at least one unmethylated cytosine, guanine dinucleotide sequence (e.g. "CpG-oligonucleotides" or DNA containing a cytosine followed by guanosine and linked by a phosphate bond) and stimulates/activates, e.g. has a mitogenic effect on, or induces or  
10 increases cytokine expression by, a vertebrate bone marrow derived cell. Preferably, as used herein, a CpG oligonucleotide is an oligonucleotide that is at least about ten nucleotides in length and includes at least one unmethylated CpG dinucleotide. The entire CpG oligodeoxynucleotide can be unmethylated or portions may be unmethylated. For example, CpGs can be useful in activating B cells, NK cells and antigen-presenting cells,  
15 such as dendritic cells, monocytes and macrophages. The CpGs can include nucleotide analogs such as analogs containing phosphorothioester bonds and can be double-stranded or single-stranded. Generally, phosphothioester stabilized CpGs are B-type CpGs while phosphodiester CpGs are A-type CpGs as indicated below.

"CpG motif": As used herein, the term "CpG motif" refers to a pattern of  
20 nucleotides that include an unmethylated central CpG, i.e. the unmethylated CpG dinucleotide, in which the C is unmethylated, surrounded by at least one base, preferably one or two nucleotides, flanking (on the 3' and the 5' side of) the central CpG. Typically and preferably, the CpG motif as used herein, comprises or alternatively consists of the unmethylated CpG dinucleotide and two nucleotides on its 5' and 3' ends. Without being  
25 bound by theory, the bases flanking the CpG confer a significant part of the activity to the CpG oligonucleotide.

A-type CpGs: As used herein, the term "A-type CpG" or "D-type CpG" refers to an oligodeoxynucleotide (ODN) comprising at least one CpG motif. The nucleotides of the at least one CpG motif are linked by at least one, typically and preferably exclusively  
30 phosphodiester (PO) bonds. Preferably, the CpG motif, and hereby preferably the CpG dinucleotide and its immediate flanking regions comprising at least one, preferably two nucleotides, are composed of phosphodiester nucleotides. Typically and preferably, the

term "A-type CpG" or "D-type CpG" as used within this specification, refers to an oligodeoxynucleotide (ODN) comprising at least one CpG motif and having poly G motifs at the 5' and/or 3' ends. Typically and preferably, the poly G motif comprises or alternatively consists of at least one, preferably at least three, at least four, at least five, at least six, at least seven, at least 8, at least 9, and more preferably at least 10 Gs (glycins). In some embodiments, the 5' and/or 3' ends, typically and preferably at least one G of the poly G motifs at the 5' and/or 3' ends, preferably at least two, three or four, even more preferably all Gs of the poly G motif, are phosphorothioate modified. In a very preferred embodiment, all Gs of the poly G motif are linked by phosphodiester bonds. A-type CpGs preferentially stimulate activation of T cells and the maturation of dendritic cells and induce the release of IFN $\alpha$ . Preferably, the A-type CpG of the invention comprises or alternatively consists of a palindromic sequence. Typically and preferably, the CpG motif is part of a palindromic sequence. Typically and preferably, all nucleotides, preferably at least the CpG motif of the palindromic sequence, are composed of phosphodiester nucleotides. Typically and preferably, the palindromic sequence is GACGATCGTC (SEQ ID NO: 16).

Immune response: As used herein, the term "immune response" refers to the systemic or local production of cytokines/chemokines/interferons. In some instances, however, the immune responses may be of low intensity and become detectable only when using at least one substance in accordance with the invention. "Immunogenic" refers to an agent used to stimulate the immune system of a living organism, so that one or more functions of the immune system are increased and directed towards the immunogenic agent.

Immunization: As used herein, the terms "immunize" or "immunization" or related terms refer to conferring the ability to mount a substantial immune response (including non-specific production of cytokines, chemokines, interferons and alike). These terms do not require that complete immunity be created, but rather that an immune response be produced which is substantially greater than baseline. For example, a mammal may be considered to be immunized if systemic or local cytokine/chemokine/interferon production can be measured.

Liposome: As used herein, the term "liposome" refers to phospholipid vesicles comprising one or more, preferably one, two, or three phospholipid bilayer membranes.

Liposomes vary in charge and in size depending on the method of preparation and the lipids used. The liposome of the present invention may be neutral, cationic, anionic, stealth, or cationic stealth. Preferably, the liposome of the invention is a cationic liposome. The liposome may have a diameter between 100 and 800 nm, preferably  
5 between 100 and 400 nm, more preferably between 100 and 300 nm, even more preferably between 100 and 200 nm, most preferably less than 200 nm. The term "liposome", as used herein, shall also encompass modified liposomes, preferably modified liposomes, wherein the surface of the liposomes may be specifically modified to optimize binding to DC, for example, via specific sugar moieties (Fukasawa et al.,  
10 (1998), FEBS, 441, 353-356) or antibodies (Serre et al. (1998), J. Immunol., 161, 6059-6067).

Oligonucleotide: As used herein, the terms "oligonucleotide" or "oligomer" refer to a nucleic acid sequence comprising 2 or more nucleotides, generally at least about 6 nucleotides to about 100,000 nucleotides, preferably about 6 to about 2000 nucleotides,  
15 and more preferably about 6 to about 300 nucleotides, even more preferably about 20 to about 300 nucleotides, and even more preferably about 20 to about 100 nucleotides. The terms "oligonucleotide" or "oligomer" also refer to a nucleic acid sequence comprising more than 100 to about 2000 nucleotides, preferably more than 100 to about 1000 nucleotides, and more preferably more than 100 to about 500 nucleotides.

20 "Oligonucleotide" also generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. The modification may comprise the backbone or nucleotide analogues.

"Oligonucleotide" includes, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded  
25 RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "oligonucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. Further, an oligonucleotide can be synthetic, genomic or recombinant, *e.g.*,  $\lambda$ -  
30 DNA, cosmid DNA, artificial bacterial chromosome, yeast artificial chromosome and filamentous phage such as M13.

The term "oligonucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. For example, suitable nucleotide modifications/analogs include peptide nucleic acid, inosin, tritylated bases, phosphorothioates, alkylphosphorothioates, 5-nitroindole deoxyribofuranosyl, 5-methyldeoxycytosine and 5,6-dihydro-5,6-dihydroxydeoxythymidine. A variety of modifications have been made to DNA and RNA; thus, "oligonucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. Other nucleotide analogs/modifications will be evident to those skilled in the art.

Effective Amount: As used herein, the term "effective amount" refers to an amount necessary or sufficient to realize a desired biologic effect. An effective amount of the composition would be the amount that achieves this selected result, and such an amount could be determined as a matter of routine by a person skilled in the art. For example, an effective amount for treating an immune system deficiency could be that amount necessary to cause activation of the immune system, resulting in the production of cytokines and alike. The term is also synonymous with "sufficient amount."

The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular composition being administered, the size of the subject, and/or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular composition of the present invention without necessitating undue experimentation.

The compositions of the invention can be combined, optionally, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human or other animal. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.

Treatment: As used herein, the terms "treatment", "treat", "treated" or "treating" refer to prophylaxis and/or therapy. When used with respect to an infectious disease, for example, the term refers to a prophylactic treatment which increases the resistance of a subject to infection with a pathogen or, in other words, decreases the likelihood that the

- 13 -

subject will become infected with the pathogen or will show signs of illness attributable to the infection, as well as a treatment after the subject has become infected in order to fight the infection, e.g., reduce or eliminate the infection or prevent it from becoming worse.

5           Vaccine: As used herein, the term "vaccine" refers to a formulation which contains the composition of the present invention and which is in a form that is capable of being administered to an animal. Typically, the vaccine comprises a conventional saline or buffered aqueous solution medium in which the composition of the present invention is suspended or dissolved. In this form, the composition of the present invention can be  
10       used conveniently to prevent, ameliorate, or otherwise treat a condition. Upon introduction into a host, the vaccine is able to provoke an immune response including, but not limited to, the production of antibodies and/or cytokines and/or the activation of cytotoxic T cells, antigen presenting cells, helper T cells, dendritic cells and/or other cellular responses.

15           Optionally, the vaccine of the present invention additionally includes an adjuvant which can be present in either a minor or major proportion relative to the compound of the present invention. The term "adjuvant" as used herein refers to non-specific stimulators of the immune response or substances that allow generation of a depot in the host which when combined with the vaccine of the present invention provide for an even  
20       more enhanced immune response. A variety of adjuvants can be used. Examples include incomplete Freund's adjuvant, aluminum hydroxide and modified muramyl dipeptide.

One, a, or an: When the terms "one," "a," or "an" are used in this disclosure, they mean "at least one" or "one or more," unless otherwise indicated.

As will be clear to those skilled in the art, certain embodiments of the invention  
25       involve the use of recombinant nucleic acid technologies such as cloning, polymerase chain reaction, the purification of DNA and RNA, the expression of recombinant proteins in prokaryotic and eukaryotic cells, etc. Such methodologies are well known to those skilled in the art and can be conveniently found in published laboratory methods manuals (e.g., Sambrook, J. et al., eds., Molecular Cloning, A Laboratory Manual, 2nd. edition,  
30       Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

2. Compositions and Methods for Enhancing of CpG-induced  $\text{INF}\alpha$ -production by liposomes:

The disclosed invention provides compositions and methods for enhancing the production of  $\text{INF}\alpha$  by CpGs in an animal. Compositions of the invention comprise, or  
 5 alternatively consist of, (a) a liposome and (b) at least one A-type CpG, wherein said A-type CpG (b) is bound to or enclosed by the liposome (a). Preferably, the A-type CpG of the invention is G10 (SEQ ID NO: 3). Furthermore, the invention provides a method for enhancing the production of  $\text{INF}\alpha$  in an animal comprising introducing into said animal a composition of the invention. In a further aspect, the invention provides a method of  
 10 immunizing or treating an animal comprising administering to the animal an immunologically effective amount of a vaccine of the invention. In addition, the invention conveniently enables the practitioner to construct such a composition for various treatment and/or prevention purposes, which include the prevention and/or treatment of infectious diseases, as well as chronic infectious diseases, the prevention  
 15 and/or treatment of cancers.

In preferred embodiment of the invention, the A-type CpG comprises or consists of a CpG motif with bases linked by phosphodiester bonds. In a further embodiment, the at least one A-type CpG of the invention comprises poly G motifs at the 5' and 3' ends, preferably wherein the G bases are phosphodiester bases. In some embodiments, the 5'  
 20 and 3' ends, typically and preferably the poly G motifs at the 5' and 3' ends, are phosphorothioate modified. In a very preferred embodiment, the CpG motif is part of a palindromic sequence.

In some embodiments, the A-type CpG oligonucleotide comprises or consists of an unmethylated CpG motif that has a sequence represented by the formula: 5'  $R_1 Y_1$ -CG-  
 25  $R_2 Y_2$  3', wherein the central CpG motif is unmethylated, and  $R_1$ ,  $R_2$ ,  $Y_1$ , and  $Y_2$  are any nucleotide. In other embodiments, the unmethylated CpG motif has a sequence represented by the formula:

5'  $R_1 Y_1 \text{CG} R_2 Y_2$  3', 5'  $R_1 Y_1 \text{CG} Y_2 R_2$  3', 5'  $R_1 R_2 \text{CG} R_3 Y_1$  3',  $R_3 Y_1 \text{CG} Y_2 Y_3$  3' or preferably 5'  $R_1 R_2 \text{CG} R_3 Y_1 \text{CG} Y_2 Y_3$  3', wherein the CpG motif is unmethylated, and  
 30 wherein  $R_1$ ,  $R_2$ , or  $R_3$  is A or G (a purine), and  $Y_1$ ,  $Y_2$ , or  $Y_3$  is C or T (a pyrimidine). In one embodiment, an A-type CpG is at least about 16 nucleotides in length and comprises or contains a sequence represented by formula: 5'-(G) $_K$ (X) $_L$ RYCGYR(W) $_M$ (G) $_N$ -3'

- 15 -

wherein the central CpG motif is unmethylated, R is a purine nucleotide, Y is a pyrimidine nucleotide, X and W are any nucleotide, K is any integer from 3 to 10, L is any integer from 0 to 10, M is any integer from 0 to 10, and N is any integer from 4 to 10.

In addition, the oligonucleotide can comprise about 6 to about 100,000  
5 nucleotides, preferably about 6 to about 2000 nucleotides, more preferably about 20 to about 2000 nucleotides, more preferably about 20 to about 300 nucleotides, more preferably about 20 to about 100 nucleotides, and even more preferably about 20 to about 40 nucleotides. In addition, the oligonucleotide can comprise more than 100 to about 2000 nucleotides, preferably more than 100 to about 1000 nucleotides, and more  
10 preferably more than 100 to about 500 nucleotides.

In one embodiment, the A-type CpG-containing oligonucleotide contains one or more phosphothioester modifications of the phosphate backbone. For example, an A-type CpG-containing oligonucleotide having one or more phosphate backbone modifications or preferably, having the phosphate backbone of the poly G motif modified, wherein one,  
15 some or all of the nucleotide phosphate backbone modifications are phosphorothioate modifications are included within the scope of the present invention. In one embodiment, the poly G motif at the 5' and 3' ends of the A-type CpG oligonucleotide, contains phosphorothioate modifications, and the CpG motif contains phosphodiester nucleotides. In a preferred embodiment, all nucleotides of the A-type CpG oligonucleotide are  
20 phosphodiester nucleotides.

The at least one unmethylated A-type CpG-containing oligonucleotide can also be recombinant, genomic, synthetic, cDNA, plasmid-derived and single or double stranded. For use in the instant invention, the nucleic acids can be synthesized de novo using any of a number of procedures well known in the art, for example, the b-cyanoethyl  
25 phosphoramidite method (Beaucage, S. L., and Caruthers, M. H., *Tet. Let.* 22:1859 (1981); nucleoside H-phosphonate method (Garegg *et al.*, *Tet. Let.* 27:4051-4054 (1986); Froehler *et al.*, *Nucl. Acid. Res.* 14:5399-5407 (1986); Garegg *et al.*, *Tet. Let.* 27:4055-4058 (1986), Gaffney *et al.*, *Tet. Let.* 29:2619-2622 (1988)). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.  
30 Alternatively, CpGs can be produced on a large scale in plasmids, (see Sambrook, T., *et al.*, "Molecular Cloning: A Laboratory Manual," Cold Spring Harbor laboratory Press, New York, 1989) which after being administered to a subject are degraded into



oligonucleotides. Oligonucleotides can be prepared from existing nucleic acid sequences (e.g., genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

In another preferred embodiment of the present invention, the CpG motif of said  
5 at least one unmethylated A-type CpG-containing oligonucleotide is part of a palindromic sequence. Preferably said palindromic sequence is GACGATCGTC (SEQ ID NO: 16). In another preferred embodiment, the palindromic sequence is flanked at its 3'-terminus and at its 5'-terminus by 10 guanosine entities, wherein preferably said palindromic sequence is GACGATCGTC (SEQ ID NO: 16). In another embodiment, said palindromic sequence  
10 is GACGATCGTC (SEQ ID NO: 16), and wherein said palindromic sequence is flanked at its 3'-terminus and at its 5'-terminus by more than two and less than 11 guanosine entities or, more preferably by 8-10 guanosine entities, or, most preferably by 10 guanosine entities.

In a preferred embodiment of the present invention, the palindromic sequence  
15 comprises, or alternatively consist essentially of, or alternatively consists of or is GACGATCGTC (SEQ ID NO: 16), and the palindromic sequence is flanked at its 5'-terminus by at least 3 and at most 10 guanosine entities and wherein said palindromic sequence is flanked at its 3'-terminus by at least 6 and at most 10 guanosine entities. In another embodiment, the palindromic sequence is flanked at its 5'-terminus by at least 3  
20 and at most 10 guanosine entities and wherein said palindromic sequence is flanked at its 3'-terminus by at least 6 and at most 10 guanosine entities.

In a further very preferred embodiment of the present invention, the at least one unmethylated A-type CpG-containing oligonucleotide comprises, or alternatively consists essentially of, or alternatively consists of a palindromic sequence, wherein at least one  
25 unmethylated A-type CpG-containing oligonucleotide comprises or consists of a nucleic acid sequence selected from the group consisting of (a) GGGGACGATCGTCGGGGGG ((SEQ ID NO: 6); and typically abbreviated herein as G3-6), (b) GGGGGACGATCGTCGGGGGG ((SEQ ID NO: 7); and typically abbreviated herein as G4-6), (c) GGGGGGACGATCGTCGGGGGG ((SEQ ID NO: 8); and typically abbreviated herein as G5-6), (d) GGGGGGGACGATCGTCGGGGGG ((SEQ ID NO: 9);  
30 and typically abbreviated herein as G6-6), (e) GGGGGGGGACGATCGTCGGGGGGG ((SEQ ID NO: 10); and typically abbreviated herein as G7-7), (f)

GGGGGGGGGACGATCGTCGGGGGGGG ((SEQ ID NO: 11); and typically abbreviated herein as G8-8), (g) GGGGGGGGGGACGATCGTCGGGGGGGG ((SEQ ID NO: 12); and typically abbreviated herein as G9-9), (h) GGGGGGCGACGACGATCGTCGTCGGGGGGG ((SEQ ID NO: 5); and typically abbreviated herein as G6), and (i) GGGGGGGGGG GACGATCGTCGGGGGGGGGG ((SEQ ID NO: 3) and typically abbreviated herein as G10).

In a further preferred embodiment of the present invention the CpG motif of the at least one unmethylated A-type CpG-containing oligonucleotide is part of a palindromic sequence, wherein said palindromic sequence is GACGATCGTC (SEQ ID NO: 16), and wherein said palindromic sequence is flanked at its 5'-terminus of at least 4 and at most 9 guanosine entities and wherein said palindromic sequence is flanked at its 3'-terminus of at least 6 and at most 9 guanosine entities.

In a further preferred embodiment of the present invention the CpG motif of the at least one unmethylated A-type CpG-containing oligonucleotide is part of a palindromic sequence, wherein said palindromic sequence is GACGATCGTC (SEQ ID NO: 16), and wherein said palindromic sequence is flanked at its 5'-terminus of at least 5 and at most 8 guanosine entities and wherein said palindromic sequence is flanked at its 3'-terminus of at least 6 and at most 8 guanosine entities.

Liposomes in the context of the present application refer to lipid vesicles consisting of a lipid bilayer that can be used to entrap or bind various drugs including CpGs. The liposome of the present invention may be selected from the group consisting of neutral liposome, anionic liposome, cationic liposome, stealth, or cationic stealth. In a preferred embodiment, the liposome is a cationic liposome. The liposome may have a diameter between 100 and 800 nm, preferably between 100 and 400 nm, more preferably between 100 and 300 nm, even more preferably between 100 and 200 nm, most preferably 200 nm.

In a preferred embodiment, the liposome exhibits positive charges in order to facilitate interaction of T cells with target cells. In some embodiments, the liposome comprises a cationic lipid, a colipid, and a stabilizing additive. In another embodiment, the liposome comprises dimethylaminoethane-carbamol-cholisterol, and/or dioleoylphosphatidylethanolamine, and/or polyethylene glycol derivatized phosphatidylethanolamine. In a preferred embodiment, the liposome comprises

phosphatidylcholine, and/or cholesterol, and/or DL- $\alpha$ -tocopherol, preferably phosphatidylcholine, cholesterol, and DL- $\alpha$ -tocopherol. Generation of such liposomes is well established e.g. in Bangham et al., (1965), J.Mol.Biol., 13, 238-252; Gursel et al., (2001), J Immunol 167: 3324; or Ludewig et al., (2000), Vaccine, 19, 23-32, the disclosure of which is incorporated herein by reference in its entirety.

In one aspect of the invention, the A-type CpGs in liposomes are used to induce systemically increased levels of IFN $\alpha$ . Such elevated levels of IFN $\alpha$  are known to be therapeutically active during hepatitis B and hepatitis C virus infection and also during infection with HIV. Moreover, IFN $\alpha$  non-specifically protects from viral and some bacterial infection, rendering A-type CpGs in liposomes ideal prophylactic “non-specific” vaccines against infections in general. In addition, local application of A-type CpGs, as eg injection into tumors, has been shown to protect from tumor growth. Thus, A-type CpGs in liposomes may be particularly attractive for the treatment of cancer.

Therefore, in a further aspect, the invention provides a method for enhancing the production of IFN $\alpha$  in an animal comprising introducing into said animal a composition of the invention.

The invention also provides vaccine compositions which can be used for preventing and/or attenuating diseases or conditions. Vaccine compositions of the invention comprise, or alternatively consist of, an immunologically effective amount of the inventive immune enhancing composition together with a pharmaceutically acceptable diluent, carrier or excipient. The vaccine can also optionally comprise an adjuvant. In a preferred embodiment, the vaccine does not comprise an antigen.

In yet another aspect, the invention provides a method of immunizing an animal or treating a disease or condition in an animal, the method comprising administering to the animal an immunologically effective amount of a composition or vaccine of the invention, wherein the disease or condition is selected from the group consisting of infectious disease (e.g. virus or parasitic infections) and cancer.

The invention further provides vaccination methods for preventing and/or attenuating diseases or conditions in animals. In one embodiment, the invention provides vaccines for the prevention of infectious diseases in a wide range of animal species, particularly mammalian species such as human, monkey, cow, dog, cat, horse, pig, etc. Vaccines can be designed to treat infections of viral etiology such as HIV, influenza,

Herpes, viral hepatitis, Epstein Barr, polio, viral encephalitis, measles, chicken pox, etc.; or infections of bacterial etiology such as pneumonia, tuberculosis, syphilis, etc.; or infections of parasitic etiology such as malaria, trypanosomiasis, leishmaniasis, trichomoniasis, amoebiasis, etc.

5           In another embodiment, the invention provides vaccines for the prevention of cancer in a wide range of species, particularly mammalian species such as human, monkey, cow, dog, cat, horse, pig, etc. Vaccines can be designed to treat all types of cancer including, but not limited to, lymphomas, carcinomas, sarcomas and melanomas.

10           In a further aspect, the present invention provides the use of a composition or a vaccine of the invention in the manufacture of a pharmaceutical for the treatment of a disorder or disease, wherein the disease or disorder is typically and preferably selected from the group consisting of cancer and infectious diseases.

15           As would be understood by one of ordinary skill in the art, when compositions of the invention are administered to an animal, they can be in a composition which contains salts, buffers, adjuvants or other substances which are desirable for improving the efficacy of the composition. Examples of materials suitable for use in preparing pharmaceutical compositions are provided in numerous sources including Remington's Pharmaceutical Sciences (Osol, A, ed., Mack Publishing Co., (1990)).

20           The compositions of the present invention can be administered by various methods known in the art. The particular mode selected will depend of course, upon the particular composition selected, the severity of the condition being treated and the dosage required for therapeutic efficacy. The methods of the invention, generally speaking, can be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, 25           parenteral, intracisternal, intravaginal, intraperitoneal, topical (as by powders, ointments, drops or transdermal patch), bucal, or as an oral or nasal spray. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion. The 30           composition of the invention can also be injected directly in a lymph node.

Dosage levels depend on the mode of administration, the nature of the subject, and the quality of the carrier/adjuvant formulation. Typical amounts are in the range of

- 20 -

about 0.1 µg to about 100 mg CpG per subject. Preferred amounts are at least about 10 µg to about 1000 µg per subject. Multiple administration to immunize the subject is preferred, and protocols are those standard in the art adapted to the subject in question.

5 The compositions can conveniently be presented in unit dosage form and can be prepared by any of the methods well-known in the art of pharmacy. Methods include the step of bringing the compositions of the invention into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compositions of the invention into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping  
10 the product.

Compositions suitable for oral administration can be presented as discrete units, such as capsules, tablets or lozenges, each containing a predetermined amount of the compositions of the invention. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, an elixir or an emulsion.

15 Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compositions of the invention described above, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art.

20 Other embodiments of the invention include processes for the production of the compositions of the invention and methods of medical treatment for cancer and allergies using said compositions.

The following examples are illustrative only and are not intended to limit the scope of the invention as defined by the appended claims. It will be apparent to those  
25 skilled in the art that various modifications and variations can be made in the methods of the present invention without departing from the spirit and scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.

30 All patents, patent applications and publications referred to herein are expressly incorporated by reference in their entirety.

Table 1: Terminology and sequences of CpG oligonucleotides used throughout the specification.

Small letters indicate deoxynucleotides connected via phosphorothioate bonds  
 5 while large letters indicate deoxynucleotides connected via phosphodiester bonds

| Terminology   | Sequence                        | SEQ ID NO |
|---------------|---------------------------------|-----------|
| 1668 (1668pt) | tccatgacgttcctgaataat           | 1         |
| 1668po        | TCCATGACG TTCCTGAATAAT          | 15        |
| 2006          | tcgtcgttttgcgttttcgt            | 2         |
| G10 (G10-PO)  | GGGGGGGGGGGACGATCGTCGGGGGGGGGG  | 3         |
| G10-PS        | gggggggggggacgatcgctggggggggggg | 4         |
| G6            | GGGGGGCGACGACGATCGTCGTCGGGGGGG  | 5         |
| G3-6          | GGGGACGATCGTCGGGGGGG            | 6         |
| G4-6          | GGGGACGATCGTCGGGGGGG            | 7         |
| G5-6          | GGGGGGACGATCGTCGGGGGGG          | 8         |
| G6-6          | GGGGGGGACGATCGTCGGGGGGG         | 9         |
| G7-7          | GGGGGGGGACGATCGTCGGGGGGGG       | 10        |
| G8-8          | GGGGGGGGGACGATCGTCGGGGGGGGG     | 11        |
| G9-9          | GGGGGGGGGGACGATCGTCGGGGGGGGGG   | 12        |
| 1826          | tccatgacgttcctgacgtt            | 14        |

## EXAMPLES

### EXAMPLE 1

10 G10 and analogues activate T cells in human blood cultures more efficiently than CpG 2006

Human peripheral blood mononuclear cells (PBMC) were isolated and stimulated with various concentrations of CpG G10, G9-9, G8-8, G7-7 or the thioester stabilized

- 22 -

CpG 2006. The next day, cells were stained for the expression of CD8 and CD69 in order to test for T cell activation. G10, G9-9, G8-8, G7-7 all efficiently activated CD8+ T cells, with G10 and G9-9 being most effective while G7-7 was least effective. In contrast, 2006 was barely able to activate human T cells (Fig 1). This characterizes G10, G9-9, G8-8, G7-7 as A type CpGs while 2006 is characterized as a B type CpG.

## EXAMPLE 2

2006 but not G10 and analogues activate B cells in human blood cultures

Human PBMC were isolated and stimulated with various concentrations of CpG G10, G9-9, G8-8, G7-7 or the thioester stabilized CpG 2006. The next day, cells were stained for the expression of CD19 and CD69 in order to test for B cell activation. G10, G9-9, G8-8, G7-7 failed to efficiently activate B cells. In contrast, 2006 was very effective at activating human B cells (Fig. 2). This characterizes G10, G9-9, G8-8, G7-7 as A type CpGs while 2006 is characterized as a B type CpG.

## EXAMPLE 3

G10 and analogues but not CpG 2006 induce production of IFN $\alpha$  in human PBMC

Human PBMC were isolated and stimulated with various concentrations of CpG G10, G9-9, G8-8, G7-7, G3, G6, G4-6 and G6-6 or the thioester stabilized CpG 2006. 24h later, supernatants were assessed for the presence of IFN $\alpha$  by ELISA. G10, G9-9, G8-8, G7-7, G3, G6, G4-6 and G6-6 all efficiently induced the production of IFN $\alpha$ , with G10 being most effective while G4-6 least effective. In contrast, 2006 was not able to induce IFN alpha release from human PBMC (Fig 3). This characterizes G10, G9-9, G8-8, G7-7 as A type CpGs while 2006 is characterized as a B type CpG.

## EXAMPLE 4

2006 and 1668 but not G10 induce production of IL-12 in human blood cultures

Human blood cells were isolated stimulated with various concentrations of CpG G10 or the thioester stabilized CpG 2006 or 1668. 24h later, presence of IL-12 was assessed in the supernatant by ELISA. G10 failed to induce production of IL-12 while both thioesterstabilized CpGs efficiently triggered the release of IL-12 (Fig 4). This characterizes G10 as A type CpGs while 2006 and 1668 are characterized as a B type CpG.

## EXAMPLE 5

10 G10 but not 2006 induces production of IFN $\alpha$  in human plasmacytoid DCs

Human plasmacytoid dendritic cells (pDCs) were isolated from PBMC by labeling them with anti-BDCA-2 mAb attached to magnetic beads (Miltenyi Biotec, Germany). pDCs were subsequently stimulated with the CpGs G10 or the phosphothioester stabilized CpG 2006 (20 nM) and release of IFN $\alpha$  into the supernatant was monitored subsequently by ELISA. Only G10 but not 2006 was able to efficiently trigger release of IFN $\alpha$  (Fig 5).

## EXAMPLE 6

Phosphothioester stabilized G10 (G10-PS) fails to stimulate T cells in human blood cultures

20 Human blood cells were isolated and stimulated with various concentrations of CpG G10 (G10-PO) or the thioester stabilized CpG G10 (G10-PS). 24h later IFN alpha released in the supernatants was measured by ELISA. G10 efficiently induced production of IFN alpha, while the thioester stabilized version was barely active. 2006 failed to induce IFN alpha secretion (Fig 6). Thus, thioester-stabilized G10 (G10-PS) does not behave as an A-type CpG (e.g. G10-PO).



## EXAMPLE 7

1668pt but not 1668po or G6 is able to enhance CTL responses in vivo

CpGs are able to non-specifically activate antigen-presenting cells. However, in vivo, usually only thioester-stabilized oligonucleotides may be active. We have previously observed that thioester stabilized CpGs are able to enhance CTL responses in vivo if mixed together with VLPs (Storni et al. (2002), J Immunol. 168: 2880). We now compared the ability of 1668pt (B type, phosphorothioate stabilized 1668) CpGs with 1668po (A-type) CpGs to enhance CTL responses upon mixing with VLPs. As a model VLP, hepatitis B core Ag fused to peptide p33 derived from LCMV was used (see WO 03/024481, Example 1). The p33-VLPs were generated as follows: Hepatitis B clone pEco63 containing the complete viral genome of Hepatitis B virus was purchased from ATCC. The gene encoding HBcAg was introduced into the EcoRI/HindIII restriction sites of expression vector pKK223.3 (Amersham Pharmacia Biotech Inc., NJ) under the control of a tac promotor. The p33 peptide (KAVYNFATM, SEQ ID NO: 13)) derived from LCMV was fused to the C-terminus of HBcAg (aa 1-183) via a three leucine-linker by standard PCR methods. E. coli K802d were transfected with the plasmid and grown in 2 liter cultures until an optical density of 1 (at 600 nm wavelength). Cells were induced by adding IPTG (Sigma, Division of Fluka AG, Switzerland) to a final concentration of 1mM for 4 hours. Bacteria were then collected by centrifugation and resuspended in 5 ml lysis buffer (10 mM Na<sub>2</sub>HPO<sub>4</sub>, 30 mM NaCl, 10 mM EDTA, 0.25 % Tween-20, pH 7.0). 200 µl of lysozyme solution (20 mg/ml) was added. After sonication 4 µl benzonase (Merck, Darmstadt, Germany) and 10 mM MgCl<sub>2</sub> were supplemented to the cell lysate. The suspension was then incubated for 30 minutes at RT and centrifuged for 15 minutes at 27000 x g. The retained supernatant was complemented with 20 % (w/v) ammonium sulfate. After incubation for 30 minutes on ice and centrifugation for 15 minutes at 48000 x g the supernatant was discarded and the pellet resuspended in 2-3 ml phosphate-saline buffer. The preparation was loaded onto a Sephacryl S-400 gel filtration column (Amersham Pharmacia Biotech Inc., NJ) for purification. Fractions were analyzed for protein content in a SDS PAGE gel and samples containing pure HBc capsids were pooled.

Electron microscopy was performed according to standard protocols.

- 25 -

Mice were immunized with 100 µg of p33-VLPs alone or mixed with 1668pt or 1668po CpGs (20 nmol). Twelve days later, mice were challenged ip (intraperitoneal) with recombinant vaccinia virus expressing LCMV GP (1 x 10<sup>6</sup> pfu, plaque forming unit) and viral titers were determined in ovaries 5 days later (Storni et al., 2002, J Immunol. 168: 2880) (Fig 7 A). Only 1668pt but not 1668po was able to enhance protective p33-specific CTL responses.

Alternatively, the bacteriophage Qβ capsid was used as VLP and co-delivered with the G6 CpG (Fig 7 B). Production and purification of Qβ is performed with the same protocol as for HBcAg VLPs. The p33 peptide was chemically coupled to the Qβ VLP via a bifunctional linker as follows: purified QβVLPs (1.5 mg/ml in 20 mM HEPES, 150 mM NaCl pH 7.2) were derivatized by a 30 min incubation at RT with a 10-fold molar excess of succinimidyl-6-(β-maleimidopropionamido)hexanoate (Pierce Biotechnology, Rockford, IL, USA). Free cross-linker was removed by extensive dialysis against 20 mM HEPES pH 7.2. Peptide p33 was produced in a modified version with three additional amino acids (GGC) added to the C-terminus (p33-GGC) (EMC microcollections GmbH, Tübingen, Germany) to allow coupling to VLPs. Derivatized Qβ VLPs and p33-GGC (peptide at 5-fold molar excess) were then incubated for 2 h at RT to allow cross-linking. Free p33-GGC was removed by dialysis against 20 mM HEPES pH 7.2 using DispoDialyser membranes with a molecular weight cut-off of 300 kD (Spectrum Medical Industries Inc., Rancho Dominguez, CA). Efficiency of cross-linking was analysed by SDS polyacrylamide gel electrophoresis.

Mice were left untreated or immunized with 90 µg of p33-VLPs mixed with G6 CpGs (20 nmol). Twelve days later, mice were challenged ip with recombinant vaccinia virus expressing LCMV GP (1 x 10<sup>6</sup> pfu) and viral titers were determined in ovaries 5 days later (Storni et al., 2002, J Immunol. 168: 2880) (Fig 7 B). G6 was not able to significantly induce protective p33-specific CTL responses.

## EXAMPLE 8

## G6 in liposomes is able to enhance p33-specific immunity

In order to test whether incorporation into liposomes may enhance the efficiency of G6, liposomes containing p33 and either G6 or 1668 were generated. Liposomes were produced as previously described (Ludewig et al, 2000, Vaccine 19, 23-32). Briefly, small unilamellar liposomes were generated by freeze-thawing followed by sequential filter extrusion. The liposomal composition was 200 mg/ml soy phosphatidylcholine, 25 mg/ml cholesterol and 1.2 mg/ml DL- $\alpha$ -tocopherol. The dried lipid mixture was solubilized with 1 mg/ml p33 peptide (KAVYNFATM, SEQ ID NO: 13) alone or with 100 nmol/ml CpGs (G6 or 1668), subjected to 3-5 freeze-thaw cycles and repeatedly extruded through Nucleopore filters of 0.8, 0.4 and 0.2  $\mu$ m pore size (Sterico AG, Dietikon, Switzerland). Unencapsulated peptide and CpGs were removed by dialysis. Liposome size was determined by laser light scattering (Submicron Particle Sizer Model 370, Nicomp, Santa Barbara, USA). Mice were vaccinated subsequently with the liposomes and p33-specific T cell responses were assessed by tetramer-staining 8 days later (Fig 8A). At day 12, mice were challenged ip with recombinant vaccinia virus expressing LCMV-GP ( $4 \times 10^6$  pfu) and viral titers were determined in ovaries 5 days later (Storni et al, 2002, J Immunol. 168: 2880) (Fig 8B). Using liposomes, both 1668 and G6 were able to enhance protective p33-specific CTL responses.

## 20 EXAMPLE 9

G10 but not 2006 in liposomes is able to enhance production of IFN $\alpha$  in vivo

In order to test whether incorporation into liposomes may enhance the ability of G10 or 2006 to trigger the in vivo production of IFN $\alpha$ , liposomes containing p33 and either G10 or 2006 are generated. Liposomes are produced as previously described (Ludewig et al, 2000, Vaccine 19, 23-32). Briefly, small unilamellar liposomes are generated by freeze-thawing followed by sequential filter extrusion. The liposomal composition is 200 mg/ml soy phosphatidylcholine, 25 mg/ml cholesterol and 1.2 mg/ml DL- $\alpha$ -tocopherol. The dried lipid mixture is solubilized with 1 mg/ml or 50  $\mu$ g/ml p33

- 27 -

peptide (KAVYNFATM, SEQ ID NO: 13) alone or with 100 nmol/ml CpGs (G10 or 2006), subjected to 3-5 freeze-thaw cycles and repeatedly extruded through Nucleopore filters of 0.8, 0.4 and 0.2  $\mu\text{m}$  pore size (Sterico AG, Dietikon, Switzerland). Unencapsulated peptide and CpGs are removed by dialysis. Liposome size is determined  
5 by laser light scattering (Submicron Particle Sizer Model 370, Nicomp, Santa Barbara, USA). Mice are vaccinated subsequently with the liposomes and production of IFN $\alpha$  is analyzed 6, 12, 18 and 24 hours later in the blood of vaccinated mice.

## WHAT IS CLAIMED IS:

1. A composition for enhancing the production of IFN $\alpha$  in an animal comprising:
  - (a) a liposome;
  - (b) at least one A-type CpG;5 wherein said A-type CpG (b) is bound to said liposome (a);
2. The composition of claim 1, wherein said at least one A-type CpG comprises at least one CpG motif, wherein the nucleotides of said at least one CpG motif are composed of phosphodiester nucleotides.
- 10 3. The composition of any one of claims 1 or 2, wherein said at least one A-type CpG comprises poly G motifs at the 5' and 3' ends, preferably wherein said G nucleotides are phosphodiester nucleotides.
- 15 4. The composition of any one of the preceding claims, wherein said at least one A-type CpG comprises the sequence 5' R<sub>1</sub>Y<sub>1</sub>-CG-R<sub>2</sub>Y<sub>2</sub> 3', and wherein R<sub>1</sub>, R<sub>2</sub>, Y<sub>1</sub>, and Y<sub>2</sub> are any nucleotide.
- 20 5. The composition of any one of claims 1 to 3, wherein said at least one A-type CpG comprises the sequence 5' R<sub>1</sub>Y<sub>1</sub>CG R<sub>2</sub>Y<sub>2</sub> 3' or 5' R<sub>1</sub>Y<sub>1</sub>CG Y<sub>2</sub> R<sub>2</sub> 3', or preferably 5' R<sub>1</sub>R<sub>2</sub>CG R<sub>3</sub>Y<sub>1</sub>CG Y<sub>2</sub> Y<sub>3</sub> 3', and wherein R<sub>1</sub>, R<sub>2</sub>, or R<sub>3</sub> is A or G, and Y<sub>1</sub>, Y<sub>2</sub>, or Y<sub>3</sub> is C or T.
- 25 6. The composition of any one of the preceding claims, wherein said A-type CpG comprises 20 to 300 nucleotides, preferably 20 to 100 nucleotides, and even more preferably 20 to 40 nucleotides.
- 30 7. The composition of any one of the preceding claims, wherein said A-type CpG, is selected from
  - (a) a recombinant oligonucleotide;
  - (b) a genomic oligonucleotide;

- 29 -

- (c) a synthetic oligonucleotide;  
(d) a plasmid-derived oligonucleotide;  
(e) a PCR product;  
(f) a single-stranded oligonucleotide; and  
5 (g) a double-stranded oligonucleotide.
8. The composition of any one of the preceding claims, wherein said at least one A-type CpG comprises, or alternatively consists essentially of, or alternatively consists of a palindromic sequence..
- 10
9. The composition of claim 8, wherein said palindromic sequence comprises, or alternatively consists essentially of, or alternatively consists of GACGATCGTC (SEQ ID NO: 16).
- 15 10. The composition of claim 9, wherein said palindromic sequence is flanked at its 5'-terminus by at least 3 and at most 10 guanosine entities and wherein said palindromic sequence is flanked at its 3'-terminus by at least 6 and at most 10 guanosine entities..
- 20 11. The composition of claim 10, wherein said A-type CpG has a nucleic acid sequence selected from
- (a) GGGGACGATCGTCGGGGGG (SEQ ID NO: 6);  
(b) GGGGGACGATCGTCGGGGGG (SEQ ID NO: 7);  
(c) GGGGGGACGATCGTCGGGGGG (SEQ ID NO: 8);  
25 (d) GGGGGGGACGATCGTCGGGGGG (SEQ ID NO: 9);  
(e) GGGGGGGGACGATCGTCGGGGGGG (SEQ ID NO: 10);  
(f) GGGGGGGGGACGATCGTCGGGGGGGG (SEQ ID NO: 11);  
(g) GGGGGGGGGGACGATCGTCGGGGGGGGG (SEQ ID NO: 12);  
(h) GGGGGGCGACGACGATCGTCGTCGGGGGGG (SEQ ID NO: 5); and  
30 (i) GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO: 3)

- 30 -

12. The composition of claim 9, wherein said at least one A-type CpG has a nucleic acid sequence of SEQ ID NO: 3.
13. The composition of any one of the preceding claims, wherein said liposome is  
5 selected from the group of:
- (a) neutral,
  - (b) anionic,
  - (c) cationic,
  - (d) stealth,
  - 10 (e) cationic stealth.
14. The composition of any one of the preceding claims, wherein said liposome is a cationic liposome.
- 15 15. A method for enhancing the production of IFN $\alpha$  in an animal, said method comprising introducing into said animal a composition of any one of the preceding claims.
16. The method of claim 15, wherein said animal is a mammal, preferably a human.  
20
17. The method of any one of claims 15 to 16, wherein said composition is introduced into said animal subcutaneously, intramuscularly, intravenously, intranasally, directly into the lymph node or locally into onto or close to a tumor.
- 25 18. A vaccine comprising an immunologically effective amount of the composition of any one of claims 1 to 14 together with a pharmaceutically acceptable diluent, carrier or excipient.
19. The vaccine of claim 18, further comprising an adjuvant.  
30
20. A method of immunizing or treating an animal comprising administering to said animal an immunologically effective amount of the vaccine of claim 18 or 19.

21. The method of claim 20, wherein said animal is a mammal, preferably a human.
22. Use of a composition according to any one of claims 1 to 14 or use of a vaccine  
5 according to claim 18 or 19 in the manufacture of a pharmaceutical for the  
treatment of a disorder or disease selected from the group consisting of cancer and  
infectious diseases.



1/8




Fig. 1

2/8




Fig. 2

3/8




Fig. 3





Fig. 4

5/8

**Fig. 5**

6/8




Fig. 6

7/8




Fig. 7B




Fig. 7A

Fig. 8B





Fig. 8A





SEQUENCE LISTING<sup>1</sup>

<110> Cytos Biotechnology AG  
 Bachmann, Martin F  
 Manolova, Vania  
 Storni, Tazio

<120> Packaged Liposomes

<130> C62898PC

<150> US 60/488,799  
 <151> 2003-07-22

<160> 16

<170> PatentIn version 3.2

<210> 1  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> CpG 1668 oligonucleotide

<220>  
 <221> misc\_feature  
 <222> (1)..(21)  
 <223> deoxynucleotides connected via phosphorothioate bonds

<400> 1  
 tccatgacgt tcctgaataa t 21

<210> 2  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> CpG-2006

<220>  
 <221> misc\_feature  
 <222> (1)..(23)  
 <223> deoxynucleotides connected via phosphorothioate bonds

<400> 2  
 tcgtcgtttt gtcgttttgt cgt 23

<210> 3  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> G10 oligonucleotide

<400> 3  
 gggggggggg gacgatcgtc gggggggggg 30

<210> 4  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> G10-PS oligonucleotide

<220>

2

<221> misc\_feature  
<222> (1)..(30)  
<223> deoxynucleotides connected via phosphorothioate bonds  
  
<400> 4  
gggggggggg gacgatcgtc gggggggggg 30  
  
<210> 5  
<211> 30  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> G6 oligonucleotide  
  
<400> 5  
ggggggcgac gacgatcgtc gtcggggggg 30  
  
<210> 6  
<211> 19  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> G3-6 oligonucleotide  
  
<400> 6  
ggggacgatc gtcgggggg 19  
  
<210> 7  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> G4-6 oligonucleotide  
  
<400> 7  
ggggggacgat cgtcgggggg 20  
  
<210> 8  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> G5-6 oligonucleotide  
  
<400> 8  
ggggggacga tcgtcggggg g 21  
  
<210> 9  
<211> 22  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> G6-6 oligonucleotide  
  
<400> 9  
gggggggacg atcgtcgggg gg 22  
  
<210> 10  
<211> 24  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> G7-7 oligonucleotide

<400> 10  
 gggggggggac gatcgctcggg gggg 24

<210> 11  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> G8-8 oligonucleotide

<400> 11  
 gggggggggga cgatcgctcgg gggggg 26

<210> 12  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> G9-9 oligonucleotide

<400> 12  
 ggggggggggg acgatcgctcg gggggggg 28

<210> 13  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> p33 peptide

<400> 13  
 Lys Ala Val Tyr Asn Phe Ala Thr Met  
 1 5

<210> 14  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> 1826 oligonucleotide

<220>  
 <221> misc\_feature  
 <222> (1)..(20)  
 <223> deoxynucleotides connected via phosphorothioate bonds

<400> 14  
 tccatgacgt tcctgacgtt 20

<210> 15  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> 1668 po oligonucleotide

<400> 15  
 tccatgacgt tcctgaataa t 21

<210> 16  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence

<220>  
<223> palindromic oligonucleotide  
<400> 16  
gacgatcgtc

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/008190

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 A61P37/04 A61K39/39 A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| X          | US 2003/060440 A1 (VERTHELYI DANIELA ET AL) 27 March 2003 (2003-03-27)<br>paragraph '0013!<br>paragraph '0105! - paragraph '0113!<br>paragraph '0116!<br>paragraph '0138!<br>paragraph '0140!<br>paragraph '0154! - paragraph '0156!<br>----- | 1, 4-8,<br>13-22      |
| X          | US 2003/087848 A1 (BRATZLER ROBERT L ET AL) 8 May 2003 (2003-05-08)   | 1-11,<br>13-22        |
| Y          | table 1<br>paragraph '0147!<br>paragraph '0147! - paragraph '0150!<br>paragraph '0169!<br>paragraph '0188!<br>-----<br>-/--   | 12                    |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

28 October 2004

Date of mailing of the international search report

23/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Irion, A

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/008190

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | US 2003/050268 A1 (BERG DANIEL J ET AL)<br>13 March 2003 (2003-03-13)  | 1-11,<br>13-22        |
| Y          | table I<br>paragraph '0158! - paragraph '0161!<br>paragraph '0098!<br>paragraph '0115!<br>paragraph '0133!<br>paragraph '0150!<br>paragraph '0158! - paragraph '0161!<br>paragraph '0044!  | 12                    |
| X          | WO 03/045431 A (SCHERING CORP)<br>5 June 2003 (2003-06-05)   | 1-11,<br>13-22        |
| Y          | page 16; table 2; sequence 2<br>page 15, line 25 - line 31<br>claims 12,14<br>page 17, line 26 - line 28   | 12                    |
| X          | WO 03/030656 A (BABIUK LORNE ALAN ; POTTER<br>ANDREW ALLAN (CA); UNIV SASKATCHEWAN<br>(CA);) 17 April 2003 (2003-04-17)  | 1-11,<br>13-22        |
| Y          | page 4, line 3 - line 8<br>page 33, line 30 - page 34, line 6<br>page 37, line 4 - line 10<br>page 23, line 22 - line 27<br>page 7, line 16 - line 19<br>page 16, line 29 - line 31<br>page 17, line 21 - line 24<br>page 33, line 30 - page 34, line 1<br>page 37, line 4 - line 7<br>page 22, line 9 - line 12<br>page 18, line 11 - line 25 | 12                    |
| P,X        | WO 2004/000351 A (RENNER WOLFGANG A ;<br>BACHMAN MARTIN F (CH); CYTOS BIOTECHNOLOGY<br>AG (CH)) 31 December 2003 (2003-12-31)<br>page 53 - page 55   | 1-22                  |
| Y          | WO 03/024481 A (BACHMANN MARTIN F ;<br>LIPOWSKY GERAD (CH); MAURER PATRICK (CH);<br>MEIJERIN) 27 March 2003 (2003-03-27)<br>page 110; table I  | 12                    |
| A          | KRUG A ET AL: "Identification of CpG<br>oligonucleotide sequences with high<br>induction of IFN-alpha/beta in<br>plasmacytoid dendritic cells"<br>EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM,<br>DE,<br>vol. 31, no. 7, July 2001 (2001-07), pages<br>2154-2163, XP002292085<br>ISSN: 0014-2980<br>the whole document                            | 1-22                  |

-/--

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| A          | <p>KRUG ANNE ET AL: "CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells."<br/>JOURNAL OF IMMUNOLOGY,<br/>vol. 170, no. 7,<br/>1 April 2003 (2003-04-01), pages<br/>3468-3477, XP002303132<br/>ISSN: 0022-1767<br/>the whole document</p>  | 1-22                  |
| A          | <p>BLACKWELL SUE E ET AL: "CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha."<br/>JOURNAL OF IMMUNOLOGY,<br/>vol. 170, no. 8,<br/>15 April 2003 (2003-04-15), pages<br/>4061-4068, XP002303133<br/>ISSN: 0022-1767<br/>the whole document</p>                             | 1-22                  |
| A          | <p>KERKMANN MIREN ET AL: "Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells."<br/>JOURNAL OF IMMUNOLOGY,<br/>vol. 170, no. 9, 1 May 2003 (2003-05-01),<br/>pages 4465-4474, XP002303134<br/>ISSN: 0022-1767<br/>the whole document</p>            | 1-22                  |
| A          | <p>WO 03/040308 A (ISHII KEN J ; KAWAKAMI KOJI (US); US GOVERNMENT (US); GURSEL IHSAN (US) 15 May 2003 (2003-05-15)<br/>cited in the application<br/>the whole document</p>   | 1-22                  |
| A          | <p>GURSEL I ET AL: "Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides"<br/>JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US,<br/>vol. 167, no. 6,<br/>15 September 2001 (2001-09-15), pages<br/>3324-3328, XP002228991<br/>ISSN: 0022-1767<br/>the whole document</p> | 1-22                  |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2004/008190

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 15-17, 20-21  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 15-17 and 20-21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

RU/EP2004/008190

| Patent document<br>cited in search report |    | Publication<br>date | Patent family<br>member(s)   | Publication<br>date                                  |
|---|----|---------------------|--|--|
| US 2003060440                             | A1 | 27-03-2003          | AU 4343700 A<br>EP 1176966 A2<br>WO 0061151 A2                       | 14-11-2000<br>06-02-2002<br>19-10-2000               |
| US 2003087848                             | A1 | 08-05-2003          | NONE   |  |
| US 2003050268                             | A1 | 13-03-2003          | NONE   |  |
| WO 03045431                               | A  | 05-06-2003          | CA 2468320 A1<br>EP 1450858 A2<br>WO 03045431 A2<br>US 2003138413 A1 | 05-06-2003<br>01-09-2004<br>05-06-2003<br>24-07-2003 |
| WO 03030656                               | A  | 17-04-2003          | WO 03030656 A2<br>EP 1455593 A2                                      | 17-04-2003<br>15-09-2004                             |
| WO 2004000351                             | A  | 31-12-2003          | WO 2004000351 A1<br>US 2004005338 A1                                 | 31-12-2003<br>08-01-2004                             |
| WO 03024481                               | A  | 27-03-2003          | EP 1450856 A2<br>WO 03024481 A2<br>US 2003099668 A1                  | 01-09-2004<br>27-03-2003<br>29-05-2003               |
| WO 03040308                               | A  | 15-05-2003          | WO 03040308 A2   | 15-05-2003   |